Skip to content
Subscriber Only

Novartis Sees Return to Growth This Year With New Chief

  • Core profit to grow by mid-to-high single digits in 2018
  • New CEO sees effort to ‘pivot even harder’ toward innovation
Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter.

Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter.

Photographer: Chris Ratcliffe/Bloomberg
Updated on

Novartis AG starts 2018 with a new chief executive and a rosier outlook, projecting a return to growth after three lackluster years.

The percentage increase in earnings excluding some expenses this year will probably be in the mid-to-high single digits, after showing no change in 2017 at constant currencies, the Basel, Switzerland-based drugmaker said in a statement Wednesday.